July 31, 2023 7:19am
Stock pricing rises or falls before and after an earnings announcement, depending on whether the earnings or LPS (loss-per-share) meet or fall short of consensus and expectation
MiMedx (MDXG) 8/1 Tuesday
Editas Medicine (EDIT), Blueprint Medicine (BPMC), Regenxbio (RGNX) and Vericel (VCEL) 8/2 Wednesday
Alnylam Pharmaceuticals (ALNY), Voyager Therapeutics (VYGR), Ultragenyx (RARE), Intellia Therapeutics (NTLA), Cellectis SA (CLLS) 8/3 Thursday
Axogen (AXGN), 8/7 Monday
Agenus (AGEN), Beam Therapeutics (BEAM), BioLife Solutions (BLFS), Fate Therapeutics (FATE), Verve Therapeutics (VERV) and bluebird bio (BLUE) 8/8 Tuesday
Ionis Pharmaceuticals (IONS) 8/9 Wednesday
Prime Medicine (PRME) 8/10 Thursday
CRISPR Therapeutics (CRSP) 8/14 Monday
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.